FY2028 EPS Estimates for OS Therapies Cut by Analyst

OS Therapies Incorporated (NYSEAMERICAN:OSTX) – Analysts at Brookline Capital Management decreased their FY2028 earnings estimates for OS Therapies in a report issued on Tuesday, November 18th. Brookline Capital Management analyst K. Raja now forecasts that the company will post earnings per share of $0.09 for the year, down from their prior estimate of $0.14. The consensus estimate for OS Therapies’ current full-year earnings is ($0.64) per share.

OS Therapies (NYSEAMERICAN:OSTX) last released its earnings results on Friday, November 14th. The company reported ($0.21) earnings per share for the quarter.

Several other equities analysts have also weighed in on the company. D. Boral Capital reissued a “buy” rating and set a $20.00 price objective on shares of OS Therapies in a report on Monday. Lake Street Capital dropped their price target on OS Therapies from $18.00 to $17.00 and set a “buy” rating on the stock in a research report on Tuesday. Finally, Zacks Research upgraded OS Therapies from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 11th. Three analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $17.33.

OS Therapies Stock Down 1.8%

Shares of OSTX stock opened at $1.62 on Wednesday. The firm has a market cap of $57.04 million, a P/E ratio of -1.98 and a beta of -4.10. The company has a 50 day moving average of $1.95 and a 200-day moving average of $1.89. OS Therapies has a 12-month low of $1.12 and a 12-month high of $7.00.

Hedge Funds Weigh In On OS Therapies

A number of hedge funds have recently bought and sold shares of the company. Susquehanna International Group LLP purchased a new stake in OS Therapies during the 3rd quarter valued at about $29,000. Mercer Global Advisors Inc. ADV purchased a new stake in shares of OS Therapies during the third quarter valued at approximately $40,000. Ground Swell Capital LLC bought a new stake in shares of OS Therapies during the third quarter valued at approximately $40,000. CM Management LLC increased its position in shares of OS Therapies by 6.7% during the third quarter. CM Management LLC now owns 400,000 shares of the company’s stock valued at $784,000 after acquiring an additional 25,000 shares in the last quarter. Finally, Bridgeway Capital Management LLC purchased a new position in OS Therapies in the 2nd quarter worth approximately $47,000.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.